BCL2 and acute myeloid leukemia: Furthermore, the enhanced expression of MCL1 in FLT3-ITD AML cells makes them more dependent on MCL1 for survival than on BCL2 during venetoclax treatment, leading to their survival advantage in this therapeutic context (66, 67).